Navigation Links
Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
Date:1/9/2012

LAKE FOREST, Ill., Jan. 9, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced enrollment of the first patient in a Phase III U.S. clinical program for its biosimilar erythropoietin (EPO). Hospira's Phase III program, which follows a successful Phase I trial that concluded last year, will compare safety and efficacy of Hospira's EPO and the reference product, Amgen's Epogen® in patients with renal (kidney) dysfunction who have anemia. Erythropoietin is a treatment for anemia associated with chronic renal failure.

The program will enroll approximately 1,000 patients on hemodialysis who have already been treated with Epogen, and will take place at more than 200 different hemodialysis centers across the United States. Results are expected in 2013.

"Patient enrollment in our Phase III EPO program is another important step as Hospira prepares to introduce safe, effective and affordable biosimilars in the United States,"  said Sumant Ramachandra, M.D., Ph.D., senior vice president, Research & Development and Medical & Regulatory Affairs, and chief scientific officer, Hospira. "We look forward to offering U.S. patients access to these important medications."

Hospira already sells a biosimilar EPO in Europe, Retacrit, and is the first and only North American-headquartered company with biosimilars on the European market and in Australia. Retacrit was introduced in early 2008, and Hospira launched Nivestim, a biosimilar version of filgrastim, in Europe in 2010 and in Australia last year. Filgrastim is a granulocyte colony-stimulating factor (G-CSF) used to treat neutropenia, a condition in which the body makes too few infection-fighting white blood cells. The condition is often ca
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections
2. Hospira to Present at the J.P. Morgan 30th Annual Healthcare Conference Jan. 10, 2012
3. Hospira Reports Third-Quarter 2011 Results
4. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
5. Hospira to Host Conference Call for Third-Quarter 2011 Results
6. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
7. Hospira to Host 2011 Investor Day
8. Hospira to Present at the Morgan Stanley Global Healthcare Conference
9. Hospira Expands Board of Directors
10. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
11. Hospira Reports Second-Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 20, 2015 ... has announced the addition of the "Cardiometabolic ... Afrezza,s discounted pricing is in line ... is critical to the product,s commercial appeal. However, ... prevent Afrezza from gaining a sizeable share of ...
(Date:7/27/2015)... WASHINGTON , July 27, 2015 Even ... Larkin , MD, FACP, NCMP, as scientific co-chair for ... health coalition to serve as an expert voice in ... treatment options for women struggling with Hypoactive Sexual Desire ... "I am honored to join Even ...
(Date:7/27/2015)... , July 20, 2015 Research and ... of the "D-dimer Testing Market - Global ... Forecast 2014 - 2022" report to their ... vitro diagnostics market is one of the fastest ... attributed to the improved health care awareness, preference ...
Breaking Medicine Technology:Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 2Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 3D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3
... (Nasdaq: VOLC ) today announced its intention to ... principal amount of convertible senior notes due September 1, 2015 ... as amended (the "Securities Act"). Prior to June 1, 2015, ... conversion, holders will receive up to the principal amount of ...
... Inc. (Nasdaq: ANDS ) announced today that it ... Friday, September 17, 2010 at 8:35 a.m. EDT (5:35 a.m. ... in Boston.  Steve Worland, Ph.D., President and Chief Executive Officer ... clinical development programs. Dr. Worland will also present ...
Cached Medicine Technology:Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 2Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 3Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 4Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 2
(Date:7/27/2015)... ... July 27, 2015 , ... Specific cardiovascular risk factors, ... brain volumes that may be early indicators of Alzheimer’s disease and dementia, according ... that vascular risk factors damage the brain and can result in cognitive impairment,” ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of Professional ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... boasting more than 700,000 members and over 200 operating Local Chapters. , “I’m pleased ...
(Date:7/27/2015)... ... July 28, 2015 , ... ... as a 2015 Professional Woman of the Year. Ms. Baum-Lappe is recognized ... organization of professional women in the country, spanning virtually every industry and profession, ...
(Date:7/27/2015)... NC (PRWEB) , ... July 27, 2015 , ... The ... the country, reported WCNC on July 7th. The rate for heroin usage ... heroin has gone down considerably, and is a less expensive alternative for those with ...
(Date:7/27/2015)... ... July 27, 2015 , ... The FSH Society , ... disease, facioscapulohumeral muscular dystrophy (FSHD), today announced the introduction of the first-ever care ... guideline is published today. , This new guideline condenses the results of ...
Breaking Medicine News(10 mins):Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3Health News:NAPW Inducts Joanne Saniewski, Principal of the Frontier School District's Big Tree Elementary, Into its VIP Woman of the Year Circle 2Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2
... Goodwin HealthDay Reporter , MONDAY, Dec. 20 (HealthDay ... histamine-2 receptor antagonists, may raise the risk of pneumonia, new ... 31 studies on heartburn drugs published between 1985 and 2009. ... suppressive drugs is associated with an increased risk of pneumonia," ...
... Horses are prone to develop genital cancer, especially as they ... mares but both sexes suffer from the condition, which is ... death. Because of the similarity of the disease to ... might be responsible. Several human genital cancers, including cervical ...
... advice are more effective than anti-inflammatory drugs and cortisone ... effects. This is the conclusion of a thesis presented ... describes, among other topics, the selection of treatment by ... elbow, and the results from a training programme for ...
... Gothenburg, Sweden, and researchers from the University of Gvle and ... in tests that ovarian cancer tissue and healthy tissue smell ... Future Oncology . In a previous project Gyrgy Horvath ... a specific scent. The dogs were able to use this ...
... Doheny HealthDay Reporter , MONDAY, Dec. 20 (HealthDay ... a new study finds that infants breast-fed for six months ... age 10 compared to bottle-fed tots, according to a new ... girls for its positive benefits," said study leader Wendy Oddy, ...
... SUNDAY, Dec. 19 (HealthDay News) -- Though holiday partying ... to partake moderately. "Research shows that drinking even ... developing cancer, including oral cancer, breast cancer and liver ... Center at the University of Texas M.D. Anderson Cancer ...
Cached Medicine News:Health News:Heartburn Drugs May Raise Pneumonia Risk 2Health News:Heartburn Drugs May Raise Pneumonia Risk 3Health News:A possible cause -- and cure -- for genital cancer in horses? 2Health News:Training the best treatment for tennis elbow 2Health News:Do Breast-Fed Baby Boys Grow Into Better Students? 2Health News:Do Breast-Fed Baby Boys Grow Into Better Students? 3Health News:Keeping Holiday Drinking in Check May Counter Cancer 2
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Cholesterol/HDL Standard 50 mg/dl....
Medicine Products: